SECONDLINE STUDY- A Randomised Open-Label Study comparing the Safety and Efficacy of Ritonavir boosted Lopinavir and 2-3N(T)RTI Backbone versus Ritonavir boosted Lopinavir and Raltegravir in Participants Virologically Failing First-Line NNRTI/2N(T)RTI Therapy